Blue-blocking glasses for manic symptoms in bipolar I
Official title: Feasibility and Preliminary Results of the Efficacy of Blue-Blocking Glasses on Manic Symptoms in Bipolar Disorder
Run by Centre Hospitalier St Anne · NCT07194278 · Data updated 2026-11-12
This project will test whether wearing blue-blocking glasses for seven days helps reduce manic symptoms and improve sleep in adults hospitalized with bipolar I manic episodes.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Centre Hospitalier St Anne Academic / other |
| Locations | 1 site (Paris, France) |
| Status | Recruiting |
| Started | July 19, 2024 |
| Main results expected | February 1, 2026 |
| Study ends | September 1, 2026 |
| Registry record updated | September 26, 2025 |
| Trial ID | NCT07194278 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults (≥18 years) hospitalized at the study site with a DSM-5 manic episode in the context of bipolar I disorder who can provide informed consent and do not have contraindicating eye conditions or pregnancy.
✕Probably not a fit
Patients who cannot consent, require urgent medical care, have severe eye disease or prior eye trauma, or are pregnant or breastfeeding are excluded and unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study examines feasibility and preliminary clinical effects of amber (blue-blocking) glasses worn continuously for seven days by adults hospitalized for a bipolar I manic episode. Participants are recruited from the adult psychiatry sector G22 at GHU-Paris (Maison Blanche - Bichat), complete clinician‑administered questionnaires at day 0, day 3, and day 7, and wear an actigraphy watch throughout the intervention. Primary outcomes focus on feasibility measures (recruitment, participation, adherence, and material feasibility) and acceptability, while secondary outcomes measure manic symptom severity, sleep parameters, global functioning, and suicidal ideation. Self-reported satisfaction and all clinical indicators are collected at the end of the seven-day participation period.
Why it matters
Potential benefit: If effective, wearing blue-blocking glasses could offer a low-risk, easy-to-use way to reduce manic symptoms and improve sleep and functioning during acute manic episodes.
How similar studies have gone: Small randomized trials and case reports have suggested that blue-blocking glasses can quickly reduce manic symptoms, but the overall evidence is limited and requires larger confirmatory studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient over 18 years old * Patient with a type 1 bipolar disorder presenting a manic episode according to the DSM-5 TR, with or without associated psychotic disorders. Exclusion Criteria: * Patient who did not agree to participate to the study * Patient unable to be informed or understand the course of the study * Patient with severe eye problem or with an history of trauma affecting the eyes * Pregnant or breastfeeding women * Patient in need of urgent care
Where it's running
-
Secteur de psychiatrie adulte G22-G23-G24
Paris, France, France Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
How childhood emotional maltreatment relates to social thinking and biology in bipolar disorder and healthy people
This study tests whether a history of emotional childhood maltreatment is linked to social cognition, brain function, and biomarkers in people with bipolar disorder and in healthy controls.
-
Understanding early psychosis and its biological markers
This study is trying to find out more about early signs of psychotic disorders like schizophrenia and bipolar disorder by looking at brain scans and other health data from around 320 participants over a year.
-
Evaluating clozapine's effectiveness in specific psychosis patients
This study is testing if clozapine works better than risperidone for people with schizophrenia, schizoaffective disorder, and bipolar I disorder who have a specific brain activity pattern.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.